Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-26T03:28:29.487Z Has data issue: false hasContentIssue false

28 - Alzheimer's disease: overview

from Part IV - Alzheimer's disease

Published online by Cambridge University Press:  04 August 2010

M. Flint Beal
Affiliation:
Cornell University, New York
Anthony E. Lang
Affiliation:
University of Toronto
Albert C. Ludolph
Affiliation:
Universität Ulm, Germany
David F. Tang-Wai
Affiliation:
Division of Neurology, University Health Network, Toronto Western Hospital, Canada
Keith A. Josephs
Affiliation:
Division of Neurology, University Health Network, Toronto Western Hospital, Canada
Ronald C. Petersen
Affiliation:
Division of Neurology, University Health Network, Toronto Western Hospital, Canada
Get access

Summary

Dementia

Dementia, itself, neither implies a specific disease nor implies a specific underlying pathology. It refers to a change in cognitive function that is severe enough to compromise an individual's daily function. The Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) defines dementia as an acquired impairment of cognitive function that includes a decline in memory beyond what would be expected for age and at least one other cognitive function, such as attention, visuospatial skills or language, or a decline in executive functioning such as planning, organization, sequencing, or abstracting. The decline cannot only affect emotional abilities, but must also interfere with work or social activities. The deficits should not be accompanied by an impairment of arousal (delirium) or be accounted for by another psychiatric condition, such as depression or schizophrenia. Dementia can further be defined by a possible, probable, or definite etiologic diagnosis. A degenerative dementia implies disease progression over time.

While the DSM-IV criteria are generally useful, one problem with the criteria is that memory impairment is an essential feature. While this is common in most dementias, other dementias may present with impairment in a non-memory cognitive domain. If the initial presentation is a change in personality or behavior, rather than memory, a frontotemporal dementia may be the diagnosis. In subjects with parkinsonism, hallucinations and fluctuations in behavior, dementia with Lewy bodies may be more likely than AD.

Type
Chapter
Information
Neurodegenerative Diseases
Neurobiology, Pathogenesis and Therapeutics
, pp. 416 - 432
Publisher: Cambridge University Press
Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alzheimer's Disease Collaborative Group (1995). The structure of the presenilin 1 (S1282) gene and identification of six novel mutations in early onset AD families. Nat. Genet., 11, 219–22CrossRef
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association
Andreasen, N., Hesse, C., Davidsson, P.et al. (1999a). Cerebrospinal fluid beta-amyloid(1–42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol., 56, 673–80CrossRefGoogle Scholar
Andeasen, N., Minthon, L., Clarberg, A.et al. (1999b). Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology, 53, 1488–94CrossRefGoogle Scholar
Arai, H., Higuchi, S. & Saskai, H. (1997). Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Gerontology, 43 (suppl 1), 2–10CrossRefGoogle ScholarPubMed
Bachman, D. L., Wolf, P. A., Linn, R.et al. (1992). Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology, 42, 115–19CrossRefGoogle ScholarPubMed
Bartenstein, P., Minoshima, S., Hirsch, C.et al (1997). Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. J. Nucl. Med., 38, 1095–101Google ScholarPubMed
Baskin, F., Rosenberg, R. N., Iyler, L., Hynan, L. & Cullum, C. M. (2000). Platelet APP isoform ratios correlate with declining cognition in AD. Neurology, 54 (10), 1907–9CrossRefGoogle ScholarPubMed
Becker, P. M., Feussner, J. R., Mulrow, C. D., Williams, B. C.& Vokaty, K. A. (1985). The role of lumbar puncture in the evaluation of dementia: the Durham Veterans Administration/Duke University Study. J. Am. Geriat. Soc., 33, 392–6CrossRefGoogle ScholarPubMed
Benson, D. F., Davis, R. J. & Snyder, B. D. (1988). Posterior cortical atrophy. Arch. Neurol., 45 (7), 789–93CrossRefGoogle ScholarPubMed
Blessed, G., Tomlinson, B. E. & Roth, M, . (1968). The association between quantitative measures of dementia and of senile changes in the cerebral gray matter of elderly subjects. Br. J. Psychiat., 114, 797–811CrossRefGoogle Scholar
Boeve, B. F., Maraganore, D. M., Parisi, J. E.et al. (1999). Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology, 53, 795–800CrossRefGoogle ScholarPubMed
Borroni, B., Colciaghi, F., Pastorino, L.et al. (2001). Amyloid precursor protein in platelets of patients with Alzheimer's disease: effect of acetylcholinerase inhibitor treatment. Arch. Neurol., 58, 442–6CrossRefGoogle Scholar
Bowen, D. M., Smith, C. B., White, P. & Davison, A. N. (1976). Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain, 99, 459–96CrossRefGoogle ScholarPubMed
Bradley, K. M., O'Sullivan, V. T., Soper, N. D. W.et al. (2002). Cerebral perfusion SPECT correlated with Braak pathological stage in Alzheimer's disease. Brain, 2002; 125, 1772–81CrossRefGoogle ScholarPubMed
Brookmeyer, R., Gray, S. & Kawas, C, . (1998). Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Hlt., 88, 1337–42CrossRefGoogle ScholarPubMed
Bush, A. I., Martins, R. N., Rumble, B.et al. (1990). The amyloid precursor protein of Alzheimer's disease is released by human platelets. J. Biol. Chem., 265 (26), 15977–83Google ScholarPubMed
Canadian Study of Health and Aging (1994). Study methods and prevalence of dementia. Can. Med. Assoc. J., 150, 899–913
Caselli, R. J. (1995). Focal and asymmetric cortical degeneration syndromes. The Neurologist, 1 (1), 1–19Google Scholar
Chung, J. A. & Cummings, J. L. (2000). Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. Neurologic Clinics, 18 (4), 829–46CrossRefGoogle ScholarPubMed
Clarke, R., Smith, A. D., Jobst, K. A., Refsum, H., Sutton, L. & Ueland, P. M. (1998). Folate, vitamin B12, and total homocyteine levels in confirmed Alzheimer's disease. Arch. Neurol., 55, 1449–55CrossRefGoogle Scholar
Clauss, J. J., Harskamp, F., Breteler, M. M.et al. (1994). The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer's disease: a population-based study. Neurology, 44, 454–61CrossRefGoogle Scholar
Corder, E. H., Saunders, A. M., Strittmatter, W. J.et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset-families. Science, 261, 921–3CrossRefGoogle ScholarPubMed
Corder, E. H., Saunders, A. M., Risch, N. J.et al. (1994). Protective effect of apolipoprotein E allele 2 for late onset Alzheimer's disease. Nat. Genet., 7, 180–4CrossRefGoogle Scholar
Cummings, J. L. & Cole, G. (2002). Alzheimer's disease. J. Am. Med. Assoc., 287 (18), 2335–8CrossRefGoogle Scholar
Davies, P. & Maloney, A. J. (1976). Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, 4, 1403CrossRefGoogle Scholar
Monte, S. M. & Wands, J. (1992). Neuronal thread protein overexpression in brains with Alzheimer's disease lesions. J. Neurol. Sci., 113, 153–64Google Scholar
Monte, S. M., Volicer, L., Hauser, S. L. & Wands, J. R. (1992). Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol., 32, 733–42CrossRefGoogle ScholarPubMed
Monte, S. M., Ghanbari, K., Frey, W. H.et al. (1997). Characterization of the AD7C-NTP DNAcDNA expression in Alzheimer's disease and measurement of a 41-kD protein in the cerebrospinal fluid. J. Clin. Invest., 100 (12), 3093–104CrossRefGoogle ScholarPubMed
Dickson, D. W. (1999). Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J. Neurol., 246 (S2), 6–15CrossRefGoogle ScholarPubMed
Di Luca, M., Pastorino, L., Bianchetti, A.et al. (1998). Differential levels of platelet amyloid β precursor protein isoforms. Arch. Neurol., 55, 1195–200CrossRefGoogle ScholarPubMed
Dodart, J. C., Bales, K. R., Gannon, K. S.et al. (2002). Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci., 5 (5), 452–7CrossRefGoogle ScholarPubMed
Doody, R. S., Stevens, J. C., Beck, C.et al.Practice parameter: management of dementia (an evidence-based review), Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 56, 1154–66CrossRef
Ertekin-Taner, N., Graff-Radford, N., Younkin, L. H.et al. (2000). Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science, 290 (5500), 2303–4CrossRefGoogle ScholarPubMed
Evans, D. A., Funkenstein, H. H., Albert, M. S.et al. (1989). Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. J. Am. Med. Assoc., 262, 2551–6CrossRefGoogle Scholar
Evans, D. A., Hebert, L. E., Beckett, L. A.et al.Education and other measures of socioeconomic status and risk of incipient Alzheimer's disease in a defined population of older persons. Arch. Neurol., 54, 1399–1405CrossRef
Folstein, M. F., Folstein, S. E. & McHugh, P. R. (1975). ‘Mini-Mental State’. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res., 12, 189–98CrossRefGoogle Scholar
Förstl, H. & Levy, R. (1991). On certain peculiar diseases of old age. Hist. Psychiatr., 2 (5, 1), 71–101Google Scholar
Fox, N. C., Warrington, E. K., Freeborough, P. A.et al. (1996). Presymptomatic hippocampal atrophy in Alzheimer's disease: a longitudinal study. Brain, 119 (6), 2001–7CrossRefGoogle Scholar
Fox, N. C., Scahill, F. I., Crum, W. R. & Rossor, M. N. (1999). Correlation between rates of brain atrophy and cognitive decline in AD. Neurology, 52 (8), 1687–9CrossRefGoogle ScholarPubMed
Fox, N. C., Crum, W. R., Scahill, R. I., Stevens, J. M., Janssen, J. C. & Rossor, M. N. (2001). Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet, 358 (9277), 201–5CrossRefGoogle ScholarPubMed
Fratiglioni, L., Albom, A., , M.iitanen & Winblad, B. (1993). Risk factors for late-onset Alzheimer's disease. Ann. Neurol., 33, 258–66CrossRefGoogle ScholarPubMed
Galasko, D., Hansen, L. A., Katzman, R.et al. (1994). Clinical–neuropathological correlations in Alzheimer's disease and related dementias. Arch. Neurol., 51 (9), 888–95CrossRefGoogle ScholarPubMed
Galasko, D., Clark, C., Chang, L.et al. (1997). Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology, 48, 632–5CrossRefGoogle ScholarPubMed
Galasko, D., Chang, L., Motter, R.et al. (1998). High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol., 55, 937–45CrossRefGoogle ScholarPubMed
Galton, C. J., Patterson, K., Xuereb, J. H. & Hodges, J. R. (2000). Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain, 123, 484–98CrossRefGoogle ScholarPubMed
Gao, S., Hendrie, H. C., Hall, K. S. & Hui, S. (1998). The relationships between age, sex, and the incidence of dementia and Alzheimer's disease. Arch. Gen. Pyschiatr., 55, 809–15CrossRefGoogle Scholar
Garrard, P. & Hodges, J. R. (2000). Semantic dementia: clinical, radiological and pathological perspectives. J. Neurol., 247, 409–22CrossRefGoogle ScholarPubMed
Gearing, M., Mirra, S. S., Hedreen, J. C., Sumi, S. M., Hansen, L. A. & Heyman, A. (1995). The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology, 45, 461–6CrossRefGoogle Scholar
Ghanbari, H., Ghanbari, K., Beheshti, I., Munzar, M., Vasauskas, A. & Averback, P. (1998). Biochemical assay for AD7C-NTP in urine as an Alzheimer's disease marker. J. Clin. Lab. Anal., 12, 285–83.0.CO;2-5>CrossRefGoogle ScholarPubMed
Graff-Radford, N. R., Green, R. C., Go, R. C.et al. (2002). Association between apolipoprotein E genotype and Alzheimer's disease in African American subjects. Arch. Neurol., 59 (4), 594–600CrossRefGoogle ScholarPubMed
Green, R. C., Cupples, L. A., Kurz, A.et al. (2003). Depression as a risk factor for Alzheimer's disease: the MIRAGE study. Arch. Neurol., 60, 753–9CrossRefGoogle ScholarPubMed
Guo, Z., Cupples, L. A., Kurz, A.et al. (2000). Head injury and the risk of AD in the MIRAGE study. Neurology, 54, 1316–23CrossRefGoogle ScholarPubMed
Hardy, J. & Gwinn-Hardy, K. 1998). Genetic classification of primary neurodegenerative disease. Science, 282, 1075–9CrossRefGoogle ScholarPubMed
Henderson, V. W., Paganini-Hill, A., Miller, B. L.et al. (2000). Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology, 54 (2), 295–301CrossRefGoogle ScholarPubMed
Hendrie, H. C., Osuntokun, B. O., Hall, K. S.et al. (1995). Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am. J. Psychiatr., 152, 1485–92Google ScholarPubMed
Hodges, J. R., Patterson, K., Oxbury, S. & Funnell, E. (1992). Semantic dementia. Brain, 115, 1783–806CrossRefGoogle ScholarPubMed
Hof, P. R., Vogt, B. A., Bouras, C. & Morrison, J. H. (1997). Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Res., 37 (24), 3609–25CrossRefGoogle ScholarPubMed
Hofman, A., Ott, A., Breteler, M. M.et al. (1997). Atherosclerosis, apolipoprotein E and the prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet, 349, 151–4CrossRefGoogle ScholarPubMed
Hulstaert, F., Blennow, K., Ivanoiu, A.et al. (1999). Improved discrimination of AD patients using beta-amyloid(1–42) and tau levels in CSF. Neurology, 52, 1555–62CrossRefGoogle ScholarPubMed
Hussain, I., Powell, D., Howlett, D. R.et al. (1999). Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol. Cell Neurosci., 14, 419–27CrossRefGoogle ScholarPubMed
in't Veld, B. A., Ruitenberg, A., Hofman, A.et al. (2001). Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med., 325 (21), 1515–21CrossRefGoogle Scholar
Jack, C. R. Jr, Petersen, R. C., Xu, Y. C.et al. (1997). Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology, 49, 786–94CrossRefGoogle ScholarPubMed
Jack, C. R. Jr, Petersen, R. C., Xu, Y. C.et al. (1999). Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology, 52, 1397–403CrossRefGoogle ScholarPubMed
Jack, C. R., Dickson, D. W., Parisi, J. E.et al. (2002). Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology, 58, 750–7CrossRefGoogle ScholarPubMed
Jagust, W., Thisted, R., Devous, M. D. Sr.et al. (2001). SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology, 56, 950–6CrossRefGoogle Scholar
Johnson, K. A., Holman, B. L., Rosen, T. J., Nagel, J. S., English, R. J. & Growdon, J. H. (1990). Iofetamine I 123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer's disease. Arch. Intern. Med., 150, 752–6CrossRefGoogle Scholar
Johnson, K. A., Kijewski, M., Becker, J., Garada, B., Satlin, A. & Holman, B. L. (1993). Quantitative brain SPECT in Alzheimer's disease and normal aging. J. Nucl. Med., 34, 2044–8Google ScholarPubMed
Kahle, P. J., Jakowec, M., Teipel1, S. J.et al. (2000). Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology, 54, 1498–504CrossRefGoogle ScholarPubMed
Katzman, R., Brown, T., Fuld, P., Peck, A., Schechter, R. & Schimmel, H. (1983). Validation of a short orientation-memory-concentration test of cognitive impairment. Am. J. Psychiatr., 140, 734–9Google Scholar
Killiany, R. J., Gomez-Isla, T., Moss, M.et al. (2000). Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann. Neurol., 47, 430–93.0.CO;2-I>CrossRefGoogle ScholarPubMed
Klünem ann, H. H., Fronhöfer, W., Wurster, H., Fischer, W., Ibach, B. & Klein, H. E. (2002). Alzheimer's second patient: Johann F and his family. Ann. Neurol., 52, 520–3CrossRefGoogle Scholar
Knopman, D. S., DeKosky, S. T., Cummings, J. L.et al. (2001). Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology, 56, 1143–53CrossRefGoogle ScholarPubMed
Kokmen, E., Beard, C. M., Offord, K. & Kurland, L. T. (1989). Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975. Neurology, 39, 773–6CrossRefGoogle Scholar
Kokmen, E., Smith, G. E., Petersen, R. C., Tangalos, E. & Ivnik, R. J. (1991). The short test of mental status: correlations with standardized psychometric testing. Arch. Neurol., 48, 725–8CrossRefGoogle ScholarPubMed
Kokmen, E. K., Beard, C. M., O'Brien, P. C. & Kurland, L. T. (1996). Epidemiology of dementia in Rochester, Minnesota. Mayo Clin. Proc., 71, 275–82CrossRefGoogle ScholarPubMed
Kramer, J. H. & Miller, B. L. (2000). Alzheimer's disease and its focal variants. Sem. Neurol., 20 (4), 447–54CrossRefGoogle ScholarPubMed
Kukull, W. A. & Ganguli, M. (2000). Epidemiology of dementia: concepts and overview. In Neurologic Clinics ed. S. DeKosky, Vol. 18, pp. 923–49. Philadelphia: W. B. SaundersCrossRef
Kurz, A., Riemenschneider, M., Buch, K.et al. (1998). Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis. Assoc. Disord., 12, 372–7CrossRefGoogle ScholarPubMed
Launer, L. J., Andersen, K., Dewey, M. E.et al. (1999). Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology, 52, 78–84CrossRefGoogle Scholar
Lee, V. Y. M., Goedert, M. & Trojanowski, J. Q. (2001). Neurodegenerative tauopathies. Ann. Rev. Neurosci., 24, 1121–59CrossRefGoogle ScholarPubMed
Levine, D. N., Lee, J. M. & Fisher, C. M. (1993). The visual variant of Alzheimer's disease: a clinicopathologic case study. Neurology, 43 (2), 305–13CrossRefGoogle ScholarPubMed
Machulda, M. M., Ward, H. A., Borowski, B.et al. (2003). Comparison of memory fMRI response among normal, MCI and Alzheimer's patients. Neurology, 61, 500–6CrossRefGoogle ScholarPubMed
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. & Stadlan, E. M. (1984). Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939–44CrossRefGoogle ScholarPubMed
Mesulam, M. M. (1982). Slowly progressive aphasia without generalized dementia. Ann. Neurol., 11, 592–8CrossRefGoogle ScholarPubMed
Mesulam, M. M. (2001). Primary progressive aphasia. Ann. Neurol., 49, 425–32CrossRefGoogle ScholarPubMed
Mohs, R. C., Doody, R. S., Morris, J. C.et al. (2001). A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 57, 481–8CrossRefGoogle ScholarPubMed
Morris, J. C. (1993). The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology, 43, 2412–14CrossRefGoogle ScholarPubMed
Mortimer, J. A. (1995). The epidemiology of Alzheimer's Disease: Beyond risk factors. In Research Advances in Alzheimer's Disease and Associated Disorders, ed. I. Iqbal, J. Mortimer, B. Winblad & H. Wisniewski. Chichester, UK: John Wiley
Müller, W. E., Mutschler, E. & Riederer, P. (1995). Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry, 28, 113–24CrossRefGoogle ScholarPubMed
Mulnard, R. A., Cotman, C. W., Kawas, C.et al. (2000). Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. J. Am. Med. Assoc., 283 (8), 1007–15CrossRefGoogle ScholarPubMed
Munoz, D. & Feldman, H. (2002). Causes of Alzheimer's disease. Can. Med. Assoc. J., 162 (1), 65–72Google Scholar
Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H. & Weller, R. O. (2003). Neuropathology of human Alzheimer's disease following immunization with amyloid beta peptide: a case report. Nat. Med., 9, 448–52CrossRefGoogle ScholarPubMed
Orgogozo, J. M., Gilman, S., Dartigues, J. F.et al. (2003). Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology, 61, 46–54CrossRefGoogle Scholar
Padovani, A., Borroni, B., Colciaghi, F.et al. (2001). Platelet amyloid precursor protein forms in AD: a peripheral diagnostic and pharmacological target. Mech. Aging Devel., 122, 1997–2004CrossRefGoogle ScholarPubMed
Petersen, R. C. (1977). Scopolamine induced learning failures in man. Psychopharmacology, 52, 283–9CrossRefGoogle ScholarPubMed
Pfiefer, M., Boncristiano, S., Bondolfi, L.et al. (2002). Cerebral hemorrhage after passive anti-Ab immunotherapy. Science, 298, 1379CrossRefGoogle Scholar
Qiu, C., Winblad, B., Fastbom, J. & Fratiglioni, L. (2003). Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology, 61, 655–60CrossRefGoogle ScholarPubMed
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S. & Möbius, H. J. (2003). Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med., 348, 1333–41CrossRefGoogle ScholarPubMed
Rogers, S., Farlow, M., Doody, R., Mohs, R. & Friedhoff, L. D. (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology, 50, 136–45CrossRefGoogle ScholarPubMed
Rosler, M., Anand, R., Cicin-Sain, A.et al. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. B. Med. J., 318, 633–8CrossRefGoogle ScholarPubMed
Ross Mackenzie, S. J., Graham, N., Stuart-Green, L.et al. (1996). Progressive biparietal atrophy: an atypical presentation of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr., 61 (4), 388–95CrossRefGoogle Scholar
Sano, M., Ernesto, C., Thomasm, R.et al. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med., 336, 1216–22CrossRefGoogle ScholarPubMed
Saunders, A. M., Strittmatter, W. J., Schmechel, D.et al. (1993). Association of apolipoprotein E allele 4 with late onset familial and sporadic Alzheimer's disease. Neurology, 43, 1467–72CrossRefGoogle ScholarPubMed
Schenk, D., Barbour, R., Dunn, W.et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173–7CrossRefGoogle ScholarPubMed
Schenk, D. (2002). Opinion. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci., 3, 824–8CrossRefGoogle Scholar
Selkoe, D. J. (2000). The genetics and molecular pathology of alzheimer's disease: roles of amyloid and the presenilins. In Neurologic Clinics, ed. S. DeKosky, pp. 903–21. Vol. 18. Philadelphia: W. B. SaundersCrossRef
Senior, K. (2002). Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 1, 3CrossRefGoogle ScholarPubMed
Seshadri, S., Drachman, D. A. & Lippa, C. F. (1995). Apolipoprotein E ε4 allele and the lifetime risk of Alzheimer's disease. Arch. Neurol., 52, 1074–9CrossRefGoogle Scholar
Seshadri, S., Beiser, A., Selhub, J.et al. (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med., 346 (7), 476–83CrossRefGoogle ScholarPubMed
Sherrington, R., Rogaev, E. I., Liang, Y.et al. (1995). Cloning of a gene bearing mis-sense mutations in early-onset familial Alzheimer's disease. Nature, 375, 754–60CrossRefGoogle Scholar
Shoji, M., Matsubara, E., Kanai, M.et al. (1998). Combination assay of CSF tau, A beta 1–40 and A beta 1–42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci., 158, 134–40CrossRefGoogle Scholar
Shumaker, S. A., Legault, C., Rapp, S. R.et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. J. Am. Med. Assoc., 289, 2651–62CrossRefGoogle ScholarPubMed
Sinha, S., Anderson, J. P., Barbour, R.et al. (1999). Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature, 402, 537–40CrossRefGoogle ScholarPubMed
Small, G., Rabins, P., Barry, P.et al. (1997). Diagnosis and treatment of Alzheimer's disease and related disorders. Consensus Statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. J. Am. Med. Assoc., 278, 1363–71CrossRefGoogle Scholar
Spillantini, M. G. & Goedert, M. (1998). Tau protein pathology in neurodegenerative diseases. Trends Neurosci., 21, 428–33CrossRefGoogle ScholarPubMed
St. George-Hyslop, P. H., Levesque, G., Levesque, L., Rommens, J., Westaway, D. & Fraser, P. E. (1996). Two homologous genes causing early-onset familial Alzheimer's disease. Cold Spring Harbor Symp. Quant. Biol., 61, 559–64Google ScholarPubMed
Stelzmann, R. A., Schnitzlein, H. N. & Murtagh, F. R. (1995). An English translation of Alzheimer's 1907 paper ‘Über eine eigenartige Erkankung der Hirnrinde’. Clin. Anat., 8 (6), 429–31CrossRefGoogle Scholar
Tang-W ai, D. F., Josephs, K. A., Boeve, B. F., Dickson, D. K., Parisi, J. E. & Petersen, R. C. (2003a). Coexistent Lewy body disease in a case of ‘visual variant Alzheimer's disease’. J. Neurol. Neurosurg. Psychiatr., 74, 389CrossRefGoogle Scholar
Tang-W ai, D. F., Josephs, K. A., Boeve, B. F., Dickson, D. K., Parisi, J. E. & Petersen, R. C. (2003b). Pathologically confirmed corticobasal degneration presenting with visuospatial dysfunction. Neurology, 61 (8), 1134–5CrossRefGoogle Scholar
Tang-W ai, D. F., Graff-Radford, N. R., Boeve, B. F.et al. (2003c). Clinical and neuropathological characteristics of posterior cortical atrophy. Neurology, 60, A264–5Google Scholar
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S. & Ding, C. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology, 54, 2269–76CrossRefGoogle ScholarPubMed
Tekin, S. & Cummings, J. L. (2001). Depression in dementia. The Neurologist, 7, 252–9CrossRefGoogle Scholar
Teng, E. L. & Chui, H. C. (1987). The Modified Mini-Mental State (3MS) examination. J. Clin. Psychiatr., 48, 314–18Google ScholarPubMed
The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group (1994). The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med., 330 (15), 1029–35CrossRef
The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group (1998). Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease. Neurobiol. Agin., 19 (2), 109–16
Gool, W. A., Walstra, G. J., Teunisse, S., Zant, F. M., Weinstein, H. C. & Royen, E. A. (1995). Diagnosing Alzheimer's disease in elderly, mildly demented patients: the impact of routine single photon emission computed tomography. J. Neurol., 242, 401–5CrossRefGoogle ScholarPubMed
Slegtenhorst, M., Lewis, J. & Hutton, M. (2000). The molecular genetics of the tauopathies. Exp. Geront., 35, 461–71CrossRefGoogle ScholarPubMed
Vassar, R., Bennett, B. D., Babu-Khan, S.et al. (1999). Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 286, 735–41CrossRefGoogle ScholarPubMed
Victoroff, J., Ross, G. W., Benson, D. F., Verity, M. A. & Vinters, H. V. (1994). Posterior cortical atrophy, Neuropathologic correlations. Arch. Neurol., 51 (3), 269–74CrossRefGoogle ScholarPubMed
Strauss, E., , iitanen, M., Ronchi, D., Winblad, B. & Fratiglioni, L. (1999). Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch. Neurol., 56, 587–92CrossRefGoogle Scholar
White, L., Petrovitch, H., Ross, G. W.et al. (1996). Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. J. Am. Med. Assoc., 276, 955–60CrossRefGoogle ScholarPubMed
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T. & DeLong, M. R. (1981). Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol., 10, 122–6CrossRefGoogle ScholarPubMed
Whitehouse, P. J., Price, D. L., Struble, R. G., Clark, A. W., Coyle, J. T. & Delon, M. R. (1982). Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science, 215, 1237–9CrossRefGoogle ScholarPubMed
Winblad, B. & Poritis, N. (1999). Memantine in severe dementia: results of the 9M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriat. Psychiatr., 14, 135–463.0.CO;2-0>CrossRefGoogle Scholar
Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G. & Siegel, G. (2000). Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol., 57, 1439–43CrossRefGoogle Scholar
Xu, Y., Jack, C. R. Jr, O'Brien, P. C.et al. (2000). Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology, 54, 1760–7CrossRefGoogle ScholarPubMed
Yan, R., Bienkowski, M. J., Shuck, M. E.et al. (1999). Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature, 402, 533–7CrossRefGoogle ScholarPubMed
Zandi, P. P., Carlson, M. C., Plassman, B. L.et al. (2002). Hormone replacement therapy and the incidence of Alzheimer's disease in older women: the Cache County study. J. Am. Med. Assoc., 288, 2123–9CrossRefGoogle ScholarPubMed
Zubenko, G. S., Zubenko, W. N., McPherson, S.et al. (2003). A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am. J. Psychiatr., 160 (5), 857–66CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×